EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Prenetics Global's enterprise value is $-24.7 Mil.
Prenetics Global's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $291.4 Mil. Therefore, Prenetics Global's EV-to-Revenue for today is -0.08.
The historical rank and industry rank for Prenetics Global's EV-to-Revenue or its related term are showing as below:
PRE'
s EV-to-Revenue Range Over the Past 10 Years
Min: -0.37 Med: -0.02 Max: 1.96
Current: -0.08
During the past 4 years, the highest EV-to-Revenue of Prenetics Global was 1.96. The lowest was -0.37. And the median was -0.02.
PRE's EV-to-Revenue is ranked better than 95.15% of 227
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.02
vs PRE: -0.08
As of today (2024-04-19), Prenetics Global's stock price is $2.90.
Prenetics Global's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $45.06. Therefore, Prenetics Global's PS Ratio for today is 0.06.
Prenetics Global EV-to-Revenue Historical Data
The historical data trend for Prenetics Global's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Prenetics Global Annual Data
Trend
Dec19
Dec20
Dec21
Dec22
EV-to-Revenue
-
-
-
0.45
Prenetics Global Quarterly Data
Dec19
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
EV-to-Revenue
1.77
0.45
-0.07
-0.07
0.10
Competitive Comparison
For the Diagnostics & Research subindustry, Prenetics Global's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prenetics Global EV-to-Revenue Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Prenetics Global's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Prenetics Global's EV-to-Revenue falls into.
Prenetics Global's current Enterprise Value is $-24.7 Mil.
Prenetics Global's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $291.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prenetics Global (NAS:PRE) EV-to-Revenue Explanation
Prenetics Global's share price for today is $2.90.
Prenetics Global's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $45.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prenetics Global EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Prenetics Global's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Prenetics Global (Prenetics Global) Business Description
Prenetics Global Ltd is a diagnostic and genetic testing company. It is a genomics and precision oncology company that has devised a method to integrate early detection for cancer, targeted therapy and direct-to-consumer genetic testing services into one comprehensive platform. It operates in two segments. The prevention segment includes the design & sale of genetics testing (including update services) & stool-based DNA tests for early colorectal cancer screening. The diagnostic segment includes the sale of COVID-19 testing services & products and precision oncology services. The majority of revenue is from the diagnostics segment. Geographically, it operates in Hong Kong and the United Kingdom, out of which the majority is from Hong Kong.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PRE has been successfully added to your 